Sicca syndrome following immune checkpoint inhibition.
The recent approval of Immunologic checkpoint inhibitors as an effective therapeutic strategy against cancer came at the cost of toxicities mediated by an excessive activation of immune system against health tissues, including among others musculoskeletal and sicca complaints.The latter occur in the context of an entity reminiscent of Sjogren's syndrome, with distinct characteristics such as abrupt onset, male predominance, lower prevalence of autoantibodies and response to steroids.
['Mavragani|Clio P|CP|', 'Moutsopoulos|Haralampos M|HM|']
D000368:Aged D001323:Autoantibodies D015496:CD4-Positive T-Lymphocytes D006801:Humans D000082082:Immune Checkpoint Inhibitors D000074324:Ipilimumab D008297:Male D009369:Neoplasms D000077594:Nivolumab D012859:Sjogren's Syndrome
Sicca syndrome Differential diagnosis Immune checkpoint inhibitors